Clarins Ever Matte Broad Spectrum Spf 15 Tint 114 label

Clarins Ever Matte Broad Spectrum Spf 15 Tint 114

Clarins Ever Matte Broad Spectrum Spf 15 Tint 114 Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Sucralfate tablets, USP are indicated in:

  • Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
  • Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.

History

There is currently no drug history available for this drug.

Other Information

Sucralfate is an α-D-glucopyranoside, β-D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex.

It has the following structural formula:

sucralfate structure

Tablets for oral administration contain 1 g of sucralfate, USP.

Also contain: povidone, magnesium stearate, and colloidal silicon dioxide.

Therapeutic category: antiulcer.

Clarins Ever Matte Broad Spectrum Spf 15 Tint 114 Manufacturers

  • Laboratoires Clarins S.a
    Clarins Ever Matte Broad Spectrum Spf 15 Tint 114 | Nostrum Laboratories, Inc.
    No Recall

    Clarins Ever Matte Broad Spectrum Spf 15 Tint 114 | Nostrum Laboratories, Inc.

    Clarins Ever Matte Broad Spectrum Spf 15 Tint 114 | Nostrum Laboratories, Inc.

    Active Duodenal Ulcer: The recommended adult oral dosage for duodenal ulcer is 1 g four times a day on an empty stomach.

    Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.

    While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.

    Maintenance Therapy: The recommended adult oral dosage is 1 g twice a day.

    Elderly: In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See PRECAUTIONS Geriatric Use)

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.